Disease Progression and Hospitalization

Add UPTRAVI® Earlier in FC II and FC III Before Progression Takes More Away

UPTRAVI® campaign 4

PRIMARY ENDPOINT: TIME TO FIRST PAH DISEASE PROGRESSION EVENT IN GRIPHON1

3.1_risk-reduction_chevron
Time to first disease progression event
Percent of patients without an event on UPTRAVI® vs placebo mobile curve
The treatment effect was established early and maintained over the entire treatment period

UPTRAVI® is the ONLY Oral Prostacyclin Pathway Therapy Proven to Reduce the Risk of Hospitalization for PAH1

GRIPHON trial: Hospitalization for PAH as the first event

Probability of hospitalization event in patients on UPTRAVI® vs placebo mobile curve

Hospitalization as first event up to end of treatment:

UPTRAVI®: 13.6% (n=78)
Placebo: 18.7% (n=109)